Abstract
Graves' orbitopathy, which affects about 25–30% of newly diagnosed patients with hyperthyroidism due to Graves' disease, 1 Tanda ML Piantanida E Liparulo L et al. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013; 98: 1443-1449 Crossref PubMed Scopus (146) Google Scholar is a multifactorial autoimmune disease causing inflammation and remodelling of orbital tissues, with relevant clinical manifestations heavily effecting the quality of life of affected individuals. 2 Neag EJ Smith TJ A 2021 update on thyroid-associated ophthalmopathy. J Endocrinol Invest. 2021; (published online Aug 20.)https://doi.org/10.1007/s40618-021-01663-9 Crossref PubMed Scopus (1) Google Scholar Considerable progress has been made in our understanding of pathogenesis of the disease 2 Neag EJ Smith TJ A 2021 update on thyroid-associated ophthalmopathy. J Endocrinol Invest. 2021; (published online Aug 20.)https://doi.org/10.1007/s40618-021-01663-9 Crossref PubMed Scopus (1) Google Scholar and in the treatment of severe forms using combination therapies (eg, intravenous glucocorticoids and mycophenolate or orbital irradiation) or novel drugs (teprotumumab, tocilizumab, and rituximab). 3 Bartalena L Kahaly GJ Baldeschi L et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021; 185: G43-G67 Crossref PubMed Scopus (24) Google Scholar Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trialAddition of oral atorvastatin to an ivGC regimen improved Graves' orbitopathy outcomes in patients with moderate-to-severe, active eye disease who were hypercholesterolaemic. Future phase 3 studies, which could potentially recruit patients regardless of low-density lipoprotein cholesterol concentration, are required to confirm this association. Full-Text PDF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
